Summary of Key Information:
Reporting Period (Quarter/Year): Quarter and Financial Year ended 31st March 2026
Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 & 33 of SEBI (LODR) Regulations, 2015
Date of Board Meeting / Approval: 29th May 2026
Audit Opinion: Unmodified opinion for both standalone and consolidated financial results.
Auditor’s Comment: Statutory Auditors M/s. Bilimoria Mehta & Co. issued an audit report with an unmodified opinion. No qualifications or modifications affecting earnings quality, internal controls, or going concern were highlighted.
Key Financial Highlights [Rs. in Lakhs]
Standalone Results:
Revenue from Operations:
- Q4 FY26: ₹410.76 lakhs (vs. Q4 FY25: ₹521.97 lakhs; YoY decrease)
- FY26: ₹1,739.18 lakhs (vs. FY25: ₹521.97 lakhs; significant YoY increase)
Total Income:
- Q4 FY26: ₹454.16 lakhs
- FY26: ₹2,088.52 lakhs
Net Profit / (Loss):
- Q4 FY26: Net Loss of ₹(898.19) lakhs
- FY26: Net Loss of ₹(1,042.29) lakhs (vs. FY25 Net Profit of ₹66.32 lakhs; material deterioration)
EPS:
- Basic EPS for FY26: ₹(0.16)
- Diluted EPS for FY26: ₹(0.15)
Other Equity: ₹24,684.13 lakhs as of 31st March 2026
Cash and Cash Equivalents: ₹113.85 lakhs as of 31st March 2026
Debt:
- Non-Current Borrowings: ₹1,296.96 lakhs
- Lease Liabilities (Non-Current): ₹2,559.81 lakhs
- Total Non-Current Liabilities: ₹3,867.17 lakhs
- Current Borrowings: Not separately specified in balance sheet breakdown provided.
Consolidated Results:
Revenue from Operations:
- Q4 FY26: ₹9,773.04 lakhs
- FY26: ₹30,857.56 lakhs
Total Income:
- Q4 FY26: ₹9,900.83 lakhs
- FY26: ₹32,088.93 lakhs
Net Profit / (Loss):
- Q4 FY26: Net Loss of ₹(711.94) lakhs
- FY26: Net Profit of ₹3,101.94 lakhs (vs. FY25 Net Profit of ₹120.79 lakhs; material improvement)
- Net Profit attributable to owners: ₹3,220.98 lakhs for FY26
EPS:
- Basic EPS for FY26: ₹0.48
- Diluted EPS for FY26: ₹0.45
Other Equity: ₹29,162.69 lakhs as of 31st March 2026
Cash and Cash Equivalents: ₹1,188.95 lakhs as of 31st March 2026
Debt:
- Non-Current Borrowings: ₹26.09 lakhs; Non-Current Lease Liabilities: ₹2,659.41 lakhs
- Current Borrowings: ₹7,209.92 lakhs; Current Lease Liabilities: ₹812.11 lakhs
Segment-wise Performance:
Segment-wise performance was not disclosed in the provided data.
Corporate Actions:
Dividend: The Board recommended a final dividend of ₹0.05 per equity share (face value Re. 1/-) for FY26. The dividend shall be paid within 30 days from the date of the ensuing Annual General Meeting (AGM), upon member approval. The AGM date was not specified.
Other Significant Information:
Subsidiaries & Associates: The consolidation includes numerous subsidiaries and associates, such as FlynnCare Health Innovations Pvt Ltd (100%), Wondertech Medical Solutions Pvt Ltd (51%), and FMV Global Innovations PTE Ltd (100%), among others listed in Annexure 1. Their financials were incorporated into the consolidated results.
Corporate Restructuring: During Q4 FY26, the company transferred its entire investment in Pellucidcare Health Innovations Pte Ltd to its wholly-owned subsidiary, Flynncare HealthCare Innovations Private Limited. This made Pellucidcare a step-down subsidiary, with no change in ultimate ownership.
Share Subdivision: Effective 12th September 2025, the company sub-divided its equity shares from ₹10/- each to 10 shares of Re. 1/- each. All per-share data (EPS) has been adjusted for comparability.
New Labour Codes: The implementation of new labour codes effective November 21, 2025, was noted. Management assessed no material impact on gratuity obligations and does not expect a material impact on other areas. The company continues to monitor relevant rules.